Acoustofluidic-based therapeutic apheresis system

Mengxi Wu, Zhiteng Ma, Xianchen Xu, Brandon Lu, Yuyang Gu, Janghoon Yoon, Jianping Xia, Zhehan Ma, Neil Upreti, Imran J. Anwar, Stuart J. Knechtle, Eileen T. Chambers, Jean Kwun (), Luke P. Lee () and Tony Jun Huang ()
Additional contact information
Mengxi Wu: Dalian University of Technology
Zhiteng Ma: Duke University
Xianchen Xu: Duke University
Brandon Lu: Duke University
Yuyang Gu: Duke University
Janghoon Yoon: Duke University Medical Center
Jianping Xia: Duke University
Zhehan Ma: Duke University
Neil Upreti: Duke University
Imran J. Anwar: Duke University Medical Center
Stuart J. Knechtle: Duke University Medical Center
Eileen T. Chambers: Duke University Medical Center
Jean Kwun: Duke University Medical Center
Luke P. Lee: Brigham and Women’s Hospital
Tony Jun Huang: Duke University

Nature Communications, 2024, vol. 15, issue 1, 1-10

Abstract: Abstract Therapeutic apheresis aims to selectively remove pathogenic substances, such as antibodies that trigger various symptoms and diseases. Unfortunately, current apheresis devices cannot handle small blood volumes in infants or small animals, hindering the testing of animal model advancements. This limitation restricts our ability to provide treatment options for particularly susceptible infants and children with limited therapeutic alternatives. Here, we report our solution to these challenges through an acoustofluidic-based therapeutic apheresis system designed for processing small blood volumes. Our design integrates an acoustofluidic device with a fluidic stabilizer array on a chip, separating blood components from minimal extracorporeal volumes. We carried out plasma apheresis in mouse models, each with a blood volume of just 280 μL. Additionally, we achieved successful plasmapheresis in a sensitized mouse, significantly lowering preformed donor-specific antibodies and enabling desensitization in a transplantation model. Our system offers a new solution for small-sized subjects, filling a critical gap in existing technologies and providing potential benefits for a wide range of patients.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-50053-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-50053-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-50053-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().